Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

10x Genomics, Inc. - Common Stock (NQ:TXG)

24.82 +1.14 (+4.84%)
Streaming Delayed Price Updated: 1:41 PM EDT, May 26, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Research
Quarterly Reports Insider Filings Other Filings

All News about 10x Genomics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
News headline image
TXG Q4 Deep Dive: Consumables Growth, Spatial Expansion, and AI-Driven Demand Shape Outlook
Biotech company 10x Genomics (NASDAQ:TXG) reported Q4 CY2025 results exceeding the market’s revenue expectations, but sales were flat year on year at $166 million. The company expects the full year’s... 
Via StockStory
Topics Artificial Intelligence
10X Genomics (NASDAQ:TXG) Posts Q4 Earnings Beat Amid Cautious 2026 Outlook ↗
Via Chartmill
Topics Earnings
News headline image
10x Genomics (TXG) Q4 2025 Earnings Transcript ↗
10x Genomics (TXG) Q4 2025 Earnings Transcript 
Via The Motley Fool
Topics Intellectual Property
News headline image
10x Genomics (NASDAQ:TXG) Delivers Impressive Q4 CY2025
Biotech company 10x Genomics (NASDAQ:TXG) reported revenue ahead of Wall Street’s expectations in Q4 CY2025, but sales were flat year on year at $166 million. The company expects the full year’s... 
Via StockStory
News headline image
10x Genomics (TXG) Reports Earnings Tomorrow: What To Expect
Biotech company 10x Genomics (NASDAQ:TXG) will be reporting earnings this Thursday after market hours. Here’s what investors should know. 
Via StockStory
Topics Artificial Intelligence World Trade
News headline image
1 Momentum Stock to Target This Week and 2 We Turn Down
The stocks featured in this article are seeing some big returns. Over the past month, they’ve outpaced the market due to some combination of positive news, upbeat results, or supportive macro... 
Via StockStory
News headline image
3 Small-Cap Stocks We’re Skeptical Of
Many small-cap stocks have limited Wall Street coverage, giving savvy investors the chance to act before everyone else catches on. But the flip side is that these businesses have increased downside... 
Via StockStory
News headline image
3 Cash-Producing Stocks That Fall Short
A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand. 
Via StockStory
News headline image
3 Unprofitable Stocks with Warning Signs
Unprofitable companies can burn through cash quickly, leaving investors exposed if they fail to turn things around. Without a clear path to profitability, these businesses risk running out of capital... 
Via StockStory
News headline image
Life Sciences Tools & Services Stocks Q3 Teardown: Illumina (NASDAQ:ILMN) Vs The Rest
Earnings results often indicate what direction a company will take in the months ahead. With Q3 behind us, let’s have a look at Illumina (NASDAQ:ILMN) and its peers. 
Via StockStory
Topics Artificial Intelligence
News headline image
3 Hyped Up Stocks That Concern Us
The stocks in this article are all trading near their 52-week highs. This strength often reflects positive developments such as new product launches, favorable industry trends, or improved financial... 
Via StockStory
News headline image
1 Healthcare Stock to Consider Right Now and 2 We Find Risky
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Players catalyzing medical advancements have benefited from elevated demand, and... 
Via StockStory
Topics Stocks
News headline image
1 Cash-Heavy Stock to Consider Right Now and 2 We Question
A cash-heavy balance sheet is often a sign of strength, but not always. Some companies avoid debt because they have weak business models, limited expansion opportunities, or inconsistent cash flow. 
Via StockStory
News headline image
Why 10x Genomics (TXG) Shares Are Falling Today
Shares of biotech company 10x Genomics (NASDAQ:TXG) fell 4.7% in the afternoon session after the company announced weak preliminary results for its fourth quarter and full year 2025, which pointed to a... 
Via StockStory
Topics Intellectual Property
News headline image
CareDx and 10x Genomics to Launch ImmuneScape™ Program – A Multiomics Research Platform to Decode Transplant Rejection and Drug Response
From CareDx, Inc.
Via Business Wire
News headline image
10x Genomics (TXG) Stock Is Up, What You Need To Know
Shares of biotech company 10x Genomics (NASDAQ:TXG) jumped 2.5% in the afternoon session after several analysts raised their price targets on the stock, pointing to a more optimistic outlook for the... 
Via StockStory
Topics Artificial Intelligence
News headline image
2 Russell 2000 Stocks Worth Investigating and 1 We Avoid
The Russell 2000 (^RUT) is home to many small-cap stocks, offering investors the chance to uncover hidden gems before the broader market catches on. However, these companies often come with higher... 
Via StockStory
News headline image
10x Genomics (TXG) Stock Trades Up, Here Is Why
Shares of biotech company 10x Genomics (NASDAQ:TXG) jumped 4.8% in the morning session after Canaccord Genuity maintained its 'Buy' rating and raised its price target on the company's shares. 
Via StockStory
Topics Artificial Intelligence
News headline image
1 Stock Under $50 Worth Your Attention and 2 We Turn Down
Stocks in the $10-50 range offer a sweet spot between affordability and stability as they’re typically more established than penny stocks. But their headline prices don’t guarantee quality, and... 
Via StockStory
News headline image
10x Genomics (TXG) Q2 2025 Earnings Transcript ↗
10x Genomics (TXG) Q2 2025 Earnings Transcript 
Via The Motley Fool
Topics Intellectual Property World Trade
News headline image
10x Genomics (TXG) Q4 2024 Earnings Transcript ↗
10x Genomics (TXG) Q4 2024 Earnings Transcript 
Via The Motley Fool
News headline image
Why 10x Genomics (TXG) Stock Is Nosediving
Shares of biotech company 10x Genomics (NASDAQ:TXG) fell 6.3% in the morning session after Citigroup downgraded the stock to Neutral from Buy. 
Via StockStory
Topics Government
News headline image
Life Sciences Tools & Services Stocks Q3 Earnings: 10x Genomics (NASDAQ:TXG) Firing on All Cylinders
The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how life sciences tools & services stocks fared in Q3, starting... 
Via StockStory
Topics Artificial Intelligence
News headline image
3 Unprofitable Stocks with Questionable Fundamentals
Running at a loss can be a red flag. Many of these businesses face mounting challenges as competition increases and funding becomes harder to secure. 
Via StockStory
News headline image
10x Genomics (TXG) Q3 2025 Earnings Transcript ↗
10x Genomics (TXG) Q3 2025 Earnings Transcript 
Via The Motley Fool
News headline image
BrightSpring Health Services, 10x Genomics, QuidelOrtho, Medpace, and Fortrea Shares Are Soaring, What You Need To Know
A number of stocks jumped in the afternoon session after reports revealed the Trump administration considered extending the Affordable Care Act (ACA) subsidies. These subsidies, which are government... 
Via StockStory
Topics Economy Government
News headline image
Bruker, 10x Genomics, PacBio, ICU Medical, and Dentsply Sirona Shares Skyrocket, What You Need To Know
A number of stocks jumped in the afternoon session after comments from a key Federal Reserve official bolstered hopes for an interest rate cut. New York Federal Reserve President John Williams stated... 
Via StockStory
Topics Economy
News headline image
3 Reasons to Avoid TXG and 1 Stock to Buy Instead
What a time it’s been for 10x Genomics. In the past six months alone, the company’s stock price has increased by a massive 73.9%, reaching $15.53 per share. This was partly thanks to its solid... 
Via StockStory
News headline image
1 Momentum Stock with Promising Prospects and 2 We Avoid
Great things are happening to the stocks in this article. They’re all outperforming the market over the last month because of positive catalysts such as a new product line, constructive news flow, or... 
Via StockStory
News headline image
5 Insightful Analyst Questions From 10x Genomics’s Q3 Earnings Call
10x Genomics delivered results in Q3 that exceeded Wall Street’s expectations, driven by robust demand in spatial biology and a steady performance in single-cell consumables. Management attributed the... 
Via StockStory
Topics Earnings
< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.